EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

3-Year Outcomes From the Amplatzer Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE)

Dhanunjaya Lakkireddy, David Thaler, Christopher R Ellis, Vijendra Swarup, Alok Gambhir, James Hermiller, Jens Erik Nielsen-Kudsk, Stephen Worthley, Devi Nair, Boris Schmidt, Rodney Horton, Nigel Gupta und 4 weitere

JACC: Cardiovascular Interventions · 2023-08 · 16 (15) · 1902-1913

DOI: 10.1016/j.jcin.2023.06.022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023-08. Verfasst von Dhanunjaya Lakkireddy und 15 weiteren Autor:innen. Beteiligte Einrichtung: Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas, USA. Electronic address: Dhanunjaya.lakkireddy@hcahealthcare.com. Hauptthemen laut MEDLINE: Atrial Appendage, Stroke, Ischemic Stroke. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The Amulet (Abbott) left atrial appendage occluder investigational device exemption trial is the largest randomized trial evaluating the safety and effectiveness of the Amulet left atrial appendage occluder compared with the Watchman 2.5 device (Boston Scientific) through 5 years. OBJECTIVES: This analysis evaluated the device effect on 3-year outcomes in the Amulet investigational device exemption trial. METHODS: The medication regimen and key clinical outcomes were reported through 3 years including: 1) the composite of ischemic stroke or systemic embolism (SE); 2) the composite of all strokes, SE, or cardiovascular (CV) death; 3) major bleeding; and 4) all-cause death and CV death. RESULTS: A total of 1,878 patients at 108 sites were randomized. A significantly higher percentage of patients were free of oral anticoagulation usage at 3 years with Amulet (96.2%) vs Watchman (92.5%) (P < 0.01). Clinical outcomes were comparable for the composite of ischemic stroke or SE (5.0% vs 4.6%; P = 0.69); the composite of all strokes, SE, or CV death (11.1% vs 12.7%; P = 0.31); major bleeding (16.1% vs 14.7%; P = 0.46); all-cause death (14.6% vs 17.9%; P = 0.08); and CV death (6.6% vs 8.5%; P = 0.14) for Amulet and Watchman, respectively. Through 3 years, device factors (device-related thrombus or peridevice leak ≥3 mm) preceded ischemic stroke events and CV deaths more frequently in Watchman compared with Amulet patients. CONCLUSIONS: The Amulet occluder demonstrated continued safety and effectiveness with over 96% free of oral anticoagulation usage through 3 years in a high-risk population compared to the Watchman device. (AMPLATZER Amulet LAA Occluder Trial [Amulet IDE]; NCT02879448).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial AppendageStrokeIschemic StrokeHumansTreatment OutcomeAnticoagulants

Stichwörter der Autor:innen

Watchmanamuletatrial fibrillationleft atrial appendage occlusionstroke

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas, USA. Electronic address: Dhanunjaya.lakkireddy@hcahealthcare.com.
  • Tufts Medical Center, Boston, Massachusetts, USA.
  • Vanderbilt Heart Institute, Nashville, Tennessee, USA.
  • Arizona Cardiovascular Research Center, Phoenix, Arizona, USA.
  • Northside Hospital Cardiovascular Institute, Atlanta, Georgia, USA.
  • St. Vincent Medical Group, Inc, Indianapolis, Indiana, USA.

Zitieren

APA

Lakkireddy, D., Thaler, D., Ellis, C. R., Swarup, V., Gambhir, A., Hermiller, J., Nielsen-Kudsk, J. E., Worthley, S., Nair, D., Schmidt, B., Horton, R., Gupta, N., Anderson, J. A., Gage, R., Alkhouli, M., & Windecker, S. (2023). 3-Year Outcomes From the Amplatzer Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE). JACC: Cardiovascular Interventions, 16(15), 1902-1913. https://doi.org/10.1016/j.jcin.2023.06.022

Vancouver

Lakkireddy D, Thaler D, Ellis CR, Swarup V, Gambhir A, Hermiller J, et al. 3-Year Outcomes From the Amplatzer Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE). JACC: Cardiovascular Interventions. 2023;16(15):1902-1913. doi:10.1016/j.jcin.2023.06.022

BibTeX
@article{Lakkireddy2023,
  author = {Lakkireddy, Dhanunjaya and Thaler, David and Ellis, Christopher R and Swarup, Vijendra and Gambhir, Alok and Hermiller, James and Nielsen-Kudsk, Jens Erik and Worthley, Stephen and Nair, Devi and Schmidt, Boris and Horton, Rodney and Gupta, Nigel and Anderson, Jordan A and Gage, Ryan and Alkhouli, Mohamad and Windecker, Stephan},
  title = {3-Year Outcomes From the Amplatzer Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE)},
  journal = {JACC: Cardiovascular Interventions},
  year = {2023},
  volume = {16},
  number = {15},
  pages = {1902--1913},
  doi = {10.1016/j.jcin.2023.06.022}
}
Kostenlos starten →